Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA DrugInvestors Business Daily • 09/23/25
Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga • 09/23/25
FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish FacilityBusiness Wire • 09/23/25
Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted TreatmentBusiness Wire • 08/14/25
Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business ProgressBusiness Wire • 08/06/25
Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025Business Wire • 07/21/25
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE TrialBusiness Wire • 06/23/25
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss StudyBenzinga • 06/18/25
Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight LossBusiness Wire • 06/18/25
Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare ConferenceBusiness Wire • 06/05/25
Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General ManagerBusiness Wire • 06/02/25
Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business ProgressBusiness Wire • 05/14/25
Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025Business Wire • 05/07/25